Drug Combination May Improve Impact of Immunotherapy in Head and Neck Cancer

Biotin: A Promising Treatment for Progressive MS
October 17, 2017
MS Risk Higher in Women with Low Levels of Vitamin D, Finnish Study Finds
October 18, 2017
Show all

Drug Combination May Improve Impact of Immunotherapy in Head and Neck Cancer

Immunotherapy can benefit head and neck cancers.

Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy’s effectiveness.

In a paper published in the journal JCI Insights on September 21, researchers report that a combination of toll-like receptors (TLR) agonists — specialized proteins that initiate immune response to foreign pathogens or, in this case, cancer cells — and other immunotherapies injected directly into a tumor suppresses tumor growth throughout the whole body.

“The mechanism reverses the phenotype of a tumor by changing its inherit properties to make the tumor more immunogenic,” said Ezra E.W. Cohen, MD, professor of medicine at UC San Diego School of Medicine and associate director for translational science at UC San Diego Moores Cancer Center and senior author on the paper. “In this study, the combination of immunotherapy drugs resulted in the complete elimination of cancer cells and even when re-challenged the tumors did not recur.”

Read full article: Drug Combination May Improve Impact of Immunotherapy in Head and Neck Cancer

Read Full Article: Drug Combination May Improve Impact of Immunotherapy in Head and Neck Cancer

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.